Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside
Cidara Therapeutics Inc. (NASDAQ:CDTX) is the top stock in our list of the hottest SMID-cap stocks so far in 2025 with a 717% share price surge year-to-date.
Cidara Therapeutics Inc. (CDTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 3,365,523 | $322,282,482 | 3.97% | |
| 2. | Point72 Asset Management Steve Cohen | 1,578,069 | $151,115,887 | +4% | 0.25% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,414,165 | $135,420,440 | +80% | 5.49% |
| 4. | Vivo Capital Albert Cha And Frank Kung | 1,311,425 | $125,582,058 | 10.11% | |
| 5. | Darwin Global Management Abhishek Trehan | 997,196 | $94,992,891 | +30% | 2.64% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.00 | 2,272,727 | $99,999,988.00 | 3,365,523 | 2025-06-26 | Filing | |
| $23.44 | 1,050 | $24,614.10 | 3,320 | 2025-06-03 | Filing | |
| $21.71 | 2,270 | $49,281.47 | 2,270 | 2025-06-02 | Filing | |
| $13.21 | 8,000 | $105,680.00 | 24,580 | 2024-06-07 | Filing | |
| $0.97 | 10,000 | $9,700.00 | 294,179 | 2023-08-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $62.86 | 474 | $29,796.92 | 31,418 | 2025-09-11 | Filing | |
| $21.96 | 1,664 | $36,542.11 | 14,674 | 2025-03-11 | Filing | |
| $21.96 | 1,773 | $38,939.69 | 16,215 | 2025-03-11 | Filing | |
| $11.64 | 924 | $10,752.31 | 23,067 | 2024-09-11 | Filing | |
| $11.64 | 909 | $10,580.12 | 17,788 | 2024-09-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,020,990 | $289,290,002 | 19.2% | |
| 2. | 1,230,666 | $117,848,576 | 0% | |
| 3. | 1,165,453 | $111,603,779 | 0% | |
| 4. | 961,164 | $92,041,065 | 2.62% | |
| 5. | 946,788 | $90,664,419 | 5.1% |
News See All
10 Hottest SMID-Cap Stocks So Far In 2025
SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.
Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck
This followed news that Cidara Therapeutics Inc.
Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid
In a statement, Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Cidara Therapeutics Q3 2025 Conference Call. [Operator Instructions] Please note, this event is being recorded.
What Makes Cidara Therapeutics (CDTX) an Investment Bet?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
11 Hot Growth Stocks to Invest in Now
On October 16, Tim Urbanowicz, Innovator Capital Management chief investment strategist, joined CNBC Television for an interview.
FDA Grants Cidara Therapeutics' CD388 Breakthrough Therapy Designation for Flu Prevention in High-Risk Patients
Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the best hot stocks to invest in.
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
Cidara Therapeutics, Inc. (CDTX) Accelerates Phase 3 Trial for Single-Dose Flu Antiviral CD388
Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics.